Companies in #Ophthalmology

ADARx Pharmaceuticals is a clinical-stage biotechnology company developing RNA-based therapeutics using its proprietary ADAR (Adenosine Deaminase Acting on RNA) editing platform. The company is allied with AbbVie and has three drugs in the clinic.

Develops, manufactures, and distributes comprehensive eye care products including surgical equipment, contact lenses, lens care solutions, and pharmaceutical products, and is expanding into cell therapy for retinal disease.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is an American generics and specialty pharmaceutical company founded in 2002 by brothers Chirag and Chintu Patel, headquartered in Bridgewater, New Jersey with major manufacturing operations in India and a growing US footprint. Amneal develops, manufactures, and distributes generic and specialty pharmaceuticals across multiple dosage forms including oral solids, injectables, topicals, and ophthalmics. The company is one of the largest US-based generic drug manufacturers and has been actively reshuffling its US footprint to focus on higher-value categories including sterile injectables, biosimilars, and complex generics. Amneal was selected in June 2026 for the FDA PreCheck Pilot Program for its new Long Island, NY facility that will manufacture small molecule sterile liquid products for pain management, respiratory and ophthalmic diseases.

Clinical-stage gene therapy company developing treatments to reverse or prevent blindness, including programs for X-linked retinoschisis, GUCY2D-associated blindness and MYO7A-associated Usher syndrome.

Medical device company developing clinically-proven precision light-filtering lenses for people living with migraine and light sensitivity. Received the first FDA De Novo authorization for a lens classification targeting migraine-associated light sensitivity.

Global eye health company developing, manufacturing and marketing vision care products, contact lenses, ophthalmic pharmaceuticals and surgical devices.

Bausch + Lomb is a public eye-health company focused on vision care, surgical ophthalmology, and ophthalmic pharmaceuticals.

Bayer (ETR: BAYN) is a diversified life sciences company headquartered in Leverkusen, Germany.

Ophthalmic gene therapy company founded to restore and improve vision in patients with rare retinal diseases; its XLRP gene therapy improved visual acuity in a pivotal trial, setting up a regulatory filing.

City Therapeutics is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines, founded by John Maraganore (former CEO of Alnylam Pharmaceuticals) and a team of RNAi pioneers. The company's lead platform is based on cleavage-inducing tiny guide RNAs (cityRNAs) designed to improve potency and durability over first-generation siRNA therapeutics, with three programs in the pipeline targeting cardiometabolic and rare diseases.

Claris Bio is a ophthalmology company. See today's news for the latest developments.

Clinical-stage ophthalmology company developing first-in-class drugs for chronic eye diseases, including CBT-001 for pterygium and CBT-004 for vascularised pinguecula.

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious eye disorders, including age-related macular degeneration (AMD) and diabetic macular edema. Its lead program, DURAVYU, is an intravitreal implant delivering a tyrosine kinase inhibitor for sustained VEGF suppression.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Ophthalmic pharmaceutical and medical device company developing therapies and surgical devices for glaucoma and corneal disorders.

Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.

Machine-learning-driven drug discovery company that builds predictive models of human disease from large-scale cellular data and patient genetics, then advances the resulting insights into small-molecule and antibody therapeutics.

IRIDEX Corporation is an ophthalmic medical-device company that develops, manufactures and markets laser-based systems, delivery devices and consumable procedure probes for the treatment of glaucoma and retinal diseases. Founded in 1989 and long headquartered in Mountain View, California, the company's intellectual property centers on its proprietary MicroPulse technology, a tissue-sparing, sub-threshold laser approach that delivers laser energy in short pulses with cooling intervals, alongside the Cyclo G6 glaucoma laser platform, the MicroPulse P3 delivery device and the G-Probe family of transscleral probes. The company completed the relocation of its manufacturing operations from Mountain View to San Jose, California in October 2026 as part of a cost-reduction programme.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye, leveraging the company's proprietary mesenchymal stem cell secretome-based technology platform. Following the May 8, 2026 1-for-50 reverse stock split (reducing outstanding shares to approximately 18.6M to address Nasdaq's $1.00 minimum bid price requirement), the company continues to operate under the KALA ticker. The January 2026 424B5 prospectus supplement established a $15M at-the-market common-stock program through H.C. Wainwright. KALA's pipeline targets ophthalmic indications with high unmet need including persistent corneal epithelial defect (PCED) and rare anterior segment inflammatory conditions.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage ophthalmic company based in Encinitas, California, developing small-molecule therapies for retinal disease. It was incorporated in 1998 and traded as EyeGate Pharmaceuticals until the November 2021 rename. Its lead programme is KIO-301, a photoswitch therapy in Phase 2 (ABACUS-2) for retinitis pigmentosa, choroideremia and Stargardt disease, partnered with Théa Open Innovation, which funds development and holds ex-Asia commercial rights. In October 2026 the company in-licensed ex-Asia rights to KIO-401 (mitucapistat), an oral calpain inhibitor for central retinal artery occlusion that has completed Phase 2 and Phase 3 studies in Japan under Senju Pharmaceutical, and it plans a multinational Phase 3 in CRAO targeted for 2027 plus a Phase 2b in NAION. Development of the DHODH inhibitor KIO-104 was discontinued in October 2026. With 13 employees and a market capitalisation around $11 million, Kiora's ability to fund a registration-scale trial — the company has said it is evaluating financing alternatives — is the central variable in the equity story.

LENZ Therapeutics is a commercial-stage biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing transformative ophthalmic therapies, led by VIZZ (aceclidine ophthalmic solution 1.44%), the first and only aceclidine-based eye drop for the treatment of presbyopia. In October 2026, LENZ initiated a corporate reorganization reducing workforce headcount by 75% (~120 roles) down to ~40 employees to focus capital on direct-to-consumer digital marketing and telehealth distribution while lowering projected 2027 OPEX by over 50%.

London-based gene therapy company developing treatments for Parkinson's disease, radiation-induced xerostomia, and inherited retinal diseases, using proprietary Riboswitch gene regulation platform.

Biotechnology company that pioneered Encapsulated Cell Therapy (ECT) to provide continuous, long-term intraocular protein delivery for retinal diseases, developer of FDA-approved ENCELTO for MacTel.

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.

Osanni Bio is a San Francisco-based biotechnology company building a pipeline of therapeutics for ophthalmology and cardiology indications. The company raised $190M in 2026 to advance its portfolio of small-molecule and biologic candidates addressing high-prevalence vision and cardiovascular diseases.

Outlook Therapeutics is a ophthalmology company. See today's news for the latest developments.

Ophthalmic medical device company (NASDAQ: SGHT) developing and commercializing surgical and nonsurgical technologies for prevalent eye diseases. Its Surgical Glaucoma segment markets the OMNI family of implant-free minimally invasive glaucoma surgery systems (OMNI Ergo, OMNI EDGE) and the SION bladeless excisional device; its Dry Eye segment markets the TearCare interventional dry eye system for evaporative dry eye disease. Q2 2026 revenue grew roughly 20% year over year, prompting the company to raise full-year 2026 revenue guidance and lower adjusted operating expense guidance, and the stock gained about 28% in a single August 2026 session.

Sling Therapeutics is a clinical-stage biopharmaceutical company in Ann Arbor, Michigan developing linsitinib, the first and only late-stage oral small-molecule IGF-1R inhibitor for the treatment of thyroid eye disease (TED).

Late clinical-stage biopharma developing therapeutic solutions for chronic diseases in eye care and beyond; lead product XDEMVY (lotilaner ophthalmic solution 0.25%) is the first and only FDA-approved treatment for Demodex blepharitis. In August 2026 it agreed to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt disease drug for $450 million.